Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

127.73USD
23 Aug 2019
Change (% chg)

$-3.54 (-2.70%)
Prev Close
$131.27
Open
$131.07
Day's High
$131.26
Day's Low
$127.13
Volume
15,714,753
Avg. Vol
7,255,049
52-wk High
$148.99
52-wk Low
$121.00

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.67
Market Cap(Mil.): $353,175.59
Shares Outstanding(Mil.): 2,655.06
Dividend: 0.95
Yield (%): 2.86

Financials

  JNJ Industry Sector
P/E (TTM): 22.06 29.73 33.85
EPS (TTM): 6.03 -- --
ROI: -- 13.04 12.69
ROE: -- 14.12 17.13

EXPLAINER: Oklahoma judge weighs if J&J created opioid public nuisance

A lawsuit by Oklahoma's attorney general accusing Johnson & Johnson of fueling the opioid epidemic is set to establish a major precedent over whether a state's public nuisance laws can be used to hold a drugmaker liable for the U.S. drug crisis.

Aug 23 2019

U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis

The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said on Wednesday.

Aug 14 2019

UPDATE 1-U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis

Aug 14 The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said on Wednesday.

Aug 14 2019

U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis

Aug 14 The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said on Wednesday.

Aug 14 2019

UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON, Aug 6 British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

Aug 06 2019

Oklahoma makes final bid to hold J&J responsible for opioid epidemic

Oklahoma's attorney general on Wednesday made his final bid to force Johnson & Johnson to pay $17 billion for its part in fueling the opioid epidemic, saying the drugmaker's "egregious" marketing caused an oversupply of addictive drugs and overdose deaths.

Jul 31 2019

REFILE-Oklahoma makes final bid to hold J&J responsible for opioid epidemic

July 31 Oklahoma's attorney general on Wednesday made his final bid to force Johnson & Johnson to pay $17 billion for its part in fueling the opioid epidemic, saying the drugmaker's "egregious" marketing caused an oversupply of addictive drugs and overdose deaths.

Jul 31 2019

J&J says FTC probing efforts to protect arthritis drug Remicade

WASHINGTON The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

Jul 29 2019

UPDATE 2-J&J says FTC probing efforts to protect arthritis drug Remicade

WASHINGTON, July 29 The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

Jul 29 2019

US STOCKS-Wall Street slips as bank earnings, Trump trade comments weigh

* Indexes fall: Dow 0.09%, S&P 0.34%, Nasdaq 0.43% (Updates to market close)

Jul 16 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates